• Legal Counsel (Jean-Luc Elhoueiss) to the venture capital firm Leap Ventures Europe SAS in connection with the organisation of its first fund raising campaign. February 2017. www.leap.vc

  • Legal Counsel (Jean-Luc Elhoueiss) to Auplata in connection with a share capital increase of M€2.5 with a waiver of shareholders’ preferential subscription rights. July 2016. www.auplata.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Pharnext in connection with its IPO on Alternext. July 2016. www.pharnext.com

  • Legal Counsel (Jean-Luc Elhoueiss) to Auplata in connection with a secondary offering of M€12 on Alternext. June 2016. www.auplata.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Auplata in connection with the free distribution on Alternext of two lines of redeemable share subscription warrants (BSAR) in favour of all shareholders, for a maximum amount of M€28.7. October 2015. www.auplata.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Pharnext in connection with the issue of a bond loan for a maximum amount of M€15. October 2015. www.pharnext.com

  • Legal Counsel (Jean-Luc Elhoueiss) to Auplata in connection with a share capital increase of M€3, with a waiver of preferential subscription rights. May 2015. www.auplata.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Auplata in connection with a secondary offering on Alternext via a share capital increase of M€5 with preferential subscription rights for shareholders. March 2015. www.auplata.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Auplata in connection with a secondary offering on Alternext via a bond issue to be subscribed in cash or a public exchange offer of M€10. June 2014. www.auplata.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to 4T Commodities and Emerging Markets in connection with its formation. May 2014. www.fourt.com

  • Legal Counsel (Jean-Luc Elhoueiss) to Theraclion in connection with its IPO on Alternext. April 2014. www.theraclion.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Pharnext in connection with the issue of a bond loan convertible into shares of an amount of M€10.6. April 2014. www.pharnext.com

  • Legal Counsel (Jean-Luc Elhoueiss) to Abivax in connection with its creation via a contribution in kind of the shares of Splicos and Wittycell. April 2014. www.abivax.com

  • Legal Counsel (Jean-Luc Elhoueiss) to Auplata in connection with a secondary offering on Alternext through a share capital increase of M€5 with preferential subscription rights for shareholders. March 2014. www.auplata.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Vexim in connection with a secondary offering on Alternext via a share capital increase with a waiver of shareholders’ preferential subscription rights in the form of a public offering of M€12, with the acquisition of an interest of M€5 by Bpi Participations. January 2014. www.vexim.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Neovacs in connection with the implementation and drawdown of a contingent equity line with Kepler Cheuvreux. December 2013. www.neovacs.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Carbios in connection with its IPO on Alternext. December 2013. www.carbios.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Deinove in connection with the implementation and drawdown of a contingent equity line with Société Générale. October 2013. www.deinove.com

  • Legal Counsel (Jean-Luc Elhoueiss) to Vexim in connection with the implementation and drawdown of a contingent equity line with Société Générale. October 2013. www.vexim.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Vexim in connection with a restricted share capital increase of M€2.5. August 2013. www.vexim.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Theraclion in connection with the issuance of a bond loan convertible into shares of an amount of M€1.4. July 2013. www.theraclion.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Carmat in connection with the implementation and drawdown of a contingent equity line with Kepler Cheuvreux. June 2013. www.carmatsa.com

  • Legal Counsel (Jean-Luc Elhoueiss) to Neovacs in connection with a secondary offering on Alternext via a share capital increase of M€7.2 with preferential subscription rights for shareholders. March 2013. www.neovacs.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Theraclion in connection with a restricted share capital increase of M€1.65. December 2012. www.theraclion.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Melanion Capital, an asset management company specialised in investments in dividend futures, in connection with its incorporation. October 2012. www.melanioncapital.com

  • Legal Counsel (Jean-Luc Elhoueiss) to Actility in connection with a restricted share capital increase of M€6.75. October 2012. www.actility.com

  • Legal Counsel (Jean-Luc Elhoueiss) to Carbios in connection with a restricted share capital increase of M€3.3 in several tranches. July 2012. www.carbios.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Pharnext in connection with restricted share capital increases for a total amount of M€13. June 2012. www.pharnext.com

  • Legal Counsel (Jean-Luc Elhoueiss) to SP3H in connection with a restricted share capital increase of M€2.2. May 2012. www.sp3h.com

  • Legal Counsel (Jean-Luc Elhoueiss) to Vexim in connection with its IPO on Alternext. May 2012. www.vexim.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Theraclion in connection with a restricted share capital increase of M€1.6. February 2012. www.theraclion.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Carmat in connection with a secondary offering on Alternext via a share capital increase of M€29.3 with preferential subscription rights for shareholders. August 2011. www.carmatsa.com

  • Legal Counsel (Jean-Luc Elhoueiss) to Neovacs in connection with a private placement of M€8 on Alternext. June 2011. www.neovacs.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Vexim in connection with share capital increases of a total amount of M€8 in 2011. www.vexim.fr

  • Legal Counsel (Jean-Luc Elhoueiss) to Pharnext in connection with restricted share capital increases of a total amount of M€10.5. May and October 2011. www.pharnext.com

  • Legal Counsel (Jean-Luc Elhoueiss) to Carmat in connection with its IPO on Alternext.July 2010. www.carmatsa.com 

  • Legal Counsel (Jean-Luc Elhoueiss) to Deinove in connection with its IPO on Alternext. April 2010. www.deinove.com 

  • Legal Counsel (Jean-Luc Elhoueiss) to Neovacs in connection with its IPO on Alternext. April 2010. www.neovacs.fr 

  • Legal Counsel (Jean-Luc Elhoueiss) to Truffle Capital, a venture capital firm that builds and invests in leading technological firms in the IT, life sciences and energy sectors, in connection with the launch of two public offerings entitled “2010 Incubator Holdings Series I” and “2010 Incubator Holdings Series II” involving the creation of sixteen holding companies known as “Holdings ISF”, under a single prospectus issued by the French securities market authority (AMF), for a financing round of a maximum amount of M€90. www.holdingsincubatrices.com

    Transaction completed in March 2010

  • Legal Counsel (Jean-Luc Elhoueiss) to the venture capital firm Truffle Capital in connection with a M€2.5 investment in shares in SP3H, a company specialised in fuel profiling. www.truffle.com

    Trasaction completed February 2010

  • Legal counsel (Erwan Cossé) to Ltkfarma during the investment made by many different private investors in the framework of the “TEPA”law.

    Transaction completed in June 2009.

  • Legal counsel (Erwan Cossé) to INL an innovative company that has designed and markets firewall authentication developed under Linux/Open Source, in the investment made by CM-CIC Capital Investissement and Cap Décisif investment funds.

    Transaction completed in February 2009
    Legal counsel to INL since December 2008.

  • Legal counsel (Erwan Cossé) to Axess Vision Technology at the investment made by OTC Asset Management and Cap Décisif investment funds.

    Transaction completed in October 2008

  • Legal counsel (Jean-Luc Elhoueiss) to EADS and of the investment-fund Truffle Capital in connection with the creation of and investment in Carmat, an innovative high tech medical start-up stemming from the joint project of Professor Alain Carpentier, an internationally renowned surgeon, and EADS to develop biomaterials and leading-edge technologies for the manufacture of the first complete artificial heart implantable in the human body.

    Transaction completed in September 2008
    Legal counsel to CARMAT since then

  • Legal counsel (Erwan Cossé) to Xentech an innovative company of medical research under contract (CRO) which offers services specializing in preclinical oncology, at the investment made by the investment fund Aurinvest Partners.

    Transaction completed in September 2008.
    Legal counsel to Xentech since January 2008.

  • Legal counsel (Erwan Cossé) to Serial Genetics an innovative, medical research company under contract (CRO) that designed and markets diagnostic medical kits, in the investment made by the investment funds G1J Ile de France and Ixcore.

    Transaction completed in June 2008
    Legal counsel to Serial Genetics since April 2008.

  • Legal counsel (Erwan Cossé) to Ltkfarma an innovative company of medical technology dedicated to the development of cell therapy products that facilitate transplants of hematopoietic stem cells for the treatment of leukemia and other severe forms of auto-immune diseases, at the investment made by several different private investors in the framework of the “TEPA” law.

    Transaction completed in June 2008
    Legal Counsel to Ltkfarma since October 2008.

  • Legal counsel (Jean-Luc Elhoueiss) to Novartis Venture Fund and to the investment fund Truffle Capital in connection with fund raising for Neovacs, a spin-off of University of Pierre and Marie Curie founded in 1993 by French immunologist Professor Daniel Zagury, focused on immunology and oncology and leader in the development of anti-cytokine and anti-viral regulatory protein therapeutic vaccines used in the treatment of certain cancers and certain inflammatory diseases.

    Transaction completed in April 2008
    Legal counsel to Neovacs since January 2008.

  • Legal Counsel (Erwan Cossé) to Axess Vision Company, an innovative start-up company of advanced scientific technology dedicated to the conception and development of a flexible endoscope for single use, at the investment made by Solar Invest (investment firm- Capital Risk).

    Transaction completed in April 2008
    Legal counsel to Axess Vision Technology since April 2008

  • Legal counsel (Erwan Cossé) to Watchfrog, an innovative start-up company of advanced scientific technology dedicated to the conception and development of transgenic models for amphibians to detect in vivo chemical, pharmaceutical, and cosmetic pollutants in an investment made by the investment fund Cap Décisif.

    Transaction completed in March 2008.
    Legal counsel to Watchfrog since 2005.

  • Legal counsel (Erwan Cossé) to W4, a software editor dedicated to Business Processing Management (BPM) at an investment made by Seventure Partners, Odyssée Venture, Ace Management and Convergent Capital investment funds

    Transaction completed in March 2008.
    Legal counsel to W4 since October 2007.

  • Legal counsel (Erwan Cossé) to Dmailer, a start up company dedicated to the conception and development of synchronization software and backup for cell phones, at an investment made by BNP Paribas Private Equity and the investment fund Alto Invest.

    Transaction completed in November 2007
    Legal counsel to Dmailer since October 2007.

  • Legal counsel (Jean-Luc Elhoueiss) to Truffle Capital and to Banexi Ventures Partners in connection with fund raising for Vexim, a company specialised in medical devices for the development and design of minimally invasive solutions for the treatment of the spine and, more precisely, spinal fractures by restoring the anatomy of the fractured vertebra.

    Transaction completed in March 2007.

  • Legal counsel (Jean-Luc Elhoueiss) to Drugabuse Sciences, a company specialised in therapies for the treatment of alcohol and drug addictions, in connection with the transfer of its assets to Elbion NV.

    Transaction completed in October 2006